T 4090
Alternative Names: Kinezodianone R hydrochloride; T-4090Latest Information Update: 13 Sep 2024
At a glance
- Originator Laboratoires Thea
- Class Antiglaucomas
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Glaucoma; Ocular hypertension
Most Recent Events
- 05 Aug 2024 Phase-II clinical trials in Glaucoma in USA (Ophthalmic) (NCT06394973)
- 05 Aug 2024 Phase-II clinical trials in Ocular hypertension in USA (Ophthalmic) (NCT06394973)
- 07 May 2024 Laboratoires Thea plans a phase II trial for Glaucoma and Ocular hypertension (Ophthalmic, Drops) in June 2024 (NCT06394973)